1. Home
  2. QTTB vs INVE Comparison

QTTB vs INVE Comparison

Compare QTTB & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$11.98

Market Cap

97.5M

Sector

Health Care

ML Signal

HOLD

Logo Identiv Inc.

INVE

Identiv Inc.

HOLD

Current Price

$3.95

Market Cap

115.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
QTTB
INVE
Founded
2015
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
97.5M
115.7M
IPO Year
2018
1997

Fundamental Metrics

Financial Performance
Metric
QTTB
INVE
Price
$11.98
$3.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$13.00
$5.50
AVG Volume (30 Days)
1.4M
73.3K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
136.78
N/A
EPS
N/A
N/A
Revenue
$53,737,000.00
$60,219,000.00
Revenue This Year
N/A
$22.10
Revenue Next Year
N/A
$20.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.21
52 Week Low
$1.40
$3.08
52 Week High
$14.85
$5.30

Technical Indicators

Market Signals
Indicator
QTTB
INVE
Relative Strength Index (RSI) 57.73 47.34
Support Level $2.93 $3.14
Resistance Level $14.85 $4.07
Average True Range (ATR) 1.56 0.17
MACD -0.15 -0.00
Stochastic Oscillator 27.43 33.42

Price Performance

Historical Comparison
QTTB
INVE

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

About INVE Identiv Inc.

Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.

Share on Social Networks: